Ilorasertib

N/A

Report date: 2024/02/08 20:00:35
NME

Base Information

Drug NameIlorasertib
Drug Alias NameIlorasertibum伊洛色替艾雷舍替A-9686600ABT-348 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonistsPlatelet-derived growth factor subunit B inhibitorsVascular endothelial growth factor receptor 2 antagonists +[8] 
TargetsVascular endothelial growth factor receptor 1Platelet-derived growth factor subunit ASerine/threonine-protein kinase Aurora-A +[8] 
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of ChicagoThe University Of Texas MD Anderson Cancer CenterAbbvie Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[7] 

Other Information

ATC CodeN/A
Related LinksKEGG